Genepharm SA

Genepharm SA is a Greek global pharmaceutical company that has been operating since 1967, with a focus on high-quality products and prioritizing people. The company has established a strong presence in both the Greek and international drug markets, distributing certified generic pharmaceutical products in over 90 countries. With a privately owned 15,000 m2 plant in Pallini, Attica, Genepharm houses advanced production lines operating under European specifications (EU GMPs). The company specializes in two categories of formulations: conventional and oncological solids, with a production capacity of 500 million tablets, 40 million capsules in solid conventional, and 140 million tablets, 10 million capsules in solid oncology. Genepharm's expertise spans across therapeutic categories such as cardiology, diabetes, oncology, urology, and antipsychotic preparations. As a well-established player in the biotechnology, manufacturing, pharmaceutical, and marketing industries, Genepharm presents a compelling investment opportunity with its robust infrastructure, broad international reach, and commitment to innovation and quality.